NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences' stock was trading at $197.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EW shares have decreased by 62.4% and is now trading at $74.14. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Thursday, April, 23rd. The medical research company reported $1.51 EPS for the quarter, beating the Zacks' consensus estimate of $1.29 by $0.22. The medical research company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.03 billion. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The company's quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the business earned $1.32 earnings per share. View Edwards Lifesciences' earnings history.

Shares of Edwards Lifesciences split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, April, 23rd. The company provided EPS guidance of $4.75-5.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.46. The company issued revenue guidance of $4.00-4.50 billion, compared to the consensus revenue estimate of $4.08 billion.

23 brokerages have issued 12-month price objectives for Edwards Lifesciences' stock. Their forecasts range from $83.00 to $300.00. On average, they anticipate Edwards Lifesciences' stock price to reach $232.77 in the next twelve months. This suggests a possible upside of 214.0% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

News articles about EW stock have been trending very positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutEdwards Lifesciences.

Edwards Lifesciences saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 2,480,000 shares, a decrease of 18.7% from the April 15th total of 3,050,000 shares. Based on an average daily trading volume, of 1,820,000 shares, the short-interest ratio is currently 1.4 days. Currently, 1.2% of the shares of the company are short sold. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Adobe (ADBE), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.03%), State Street Corp (4.36%), Bank of New York Mellon Corp (3.17%), Wellington Management Group LLP (3.10%), Capital International Investors (2.50%) and Sands Capital Management LLC (2.14%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Sands Capital Management LLC, Nuveen Asset Management LLC, Capital Research Global Investors, APG Asset Management N.V., Disciplined Growth Investors Inc. MN, Massachusetts Financial Services Co. MA, and Two Sigma Investments LP. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem, and William J Phd Link. View insider buying and selling activity for Edwards Lifesciences.

EW stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Fisher Asset Management LLC, Alliancebernstein L.P., Capital International Investors, Carmignac Gestion, BlackRock Inc., Bank of New York Mellon Corp, and MERIAN GLOBAL INVESTORS UK Ltd. View insider buying and selling activity for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $74.14.

Edwards Lifesciences has a market capitalization of $15.31 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]